Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Ebiomedicine|August 30, 2019
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancersLivingstone Fultang, Silvia Panetti, Margaret Ng, et al.
Cancer Research|June 10, 2015
Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered ImmunityFrancis Mussai, Sharon Egan, Stuart Hunter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid LeukemiaCharles Craddock, Daniel Slade, Carmela De Santo, et al.
Journal of Leukocyte Biology|June 18, 2026
The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase II single arm, open label trialCarmela De Santo, Aimee Jackson, Francis Mussai, et al.
Blood|February 25, 2015
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic targetFrancis Mussai, Sharon Egan, Joseph Higginbotham-Jones, et al.
Blood Advances|December 15, 2022
Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environmentSilvia Panetti, Nicola McJannett, Livingstone Fultang, et al.
Blood|June 24, 2020
Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activityLivingstone Fultang, Sarah Booth, Orli Yogev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2018
Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma PatientsSwati Khanna, Suzanne Graef, Francis Mussai, et al.
British Journal of Haematology|November 22, 2022
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trialFrancis Mussai, Carmela De Santo, Paul Cheng, et al.
EMBO Reports|July 25, 2023
Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cellsKevin M Rattigan, Martha M Zarou, Zuzana Brabcova, et al.
Pageof 4